We are live on ! Find out more
DA

DSC Advisors Portfolio holdings

AUM $11M
1-Year Est. Return 5.88%
This Fund
S&P 500
This Quarter Est. Return
+9.3%
1 Year Est. Return
+5.88%
3 Year Est. Return
+3.18%
5 Year Est. Return
+39.43%
10 Year Est. Return
+114.64%
AUM
$129M
AUM Growth
+$31M
Cap. Flow
+$24.2M
Cap. Flow %
18.73%
Top 10 Hldgs %
72.18%
Holding
83
New
11
Increased
21
Reduced
34
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
2
ZBH icon
Zimmer Biomet
ZBH
+$5.47M
3
VYNE icon
VYNE Therapeutics
VYNE
+$1.73M
4
GENI icon
Genius Sports
GENI
+$674K
5
HYRE
HyreCar Inc. Common Stock
HYRE
+$594K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$5.43M
2
EHTH icon
eHealth
EHTH
+$1.66M
3
X
US Steel
X
+$769K
4
COMS
COMSovereign Holding Corp. Common Stock
COMS
+$725K
5
RTX icon
RTX Corp
RTX
+$284K

Sector Composition

Rank Sector Weight
1 Healthcare 32.19%
2 Technology 9.61%
3 Communication Services 9.37%
4 Financials 9.33%
5 Consumer Discretionary 2.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$466B
$39.8M 30.74%
+100,000
New +$38.6M
CVS icon
2
CVS Health
CVS
$137B
$11.3M 8.76%
109,884
-135
-0.1% -$12.5K
COR icon
3
Cencora
COR
$59.9B
$8.64M 6.67%
65,000
– –
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.22T
$6.66M 5.14%
46,000
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.18M 4.78%
+70,000
New +$5.78M
ATH
6
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$5.29M 4.09%
63,500
– –
ZBH icon
7
Zimmer Biomet
ZBH
$17.6B
$5.15M 3.98%
+41,771
New +$5.47M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.68M 3.62%
160,000
– –
BMRN icon
9
PUT
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.09M 2.39%
+35,000
New +$2.89M
VYNE icon
10
VYNE Therapeutics
VYNE
$25.4M
$2.6M 2.01%
141,722
+80,611
+132% +$1.73M
GOOGL icon
11
Alphabet (Google) Class A
GOOGL
$4.23T
$1.99M 1.54%
13,760
-360
-3% -$51.8K
MSFT icon
12
Microsoft
MSFT
$2.93T
$1.99M 1.54%
5,915
-846
-13% -$274K
AAPL icon
13
Apple
AAPL
$4.9T
$1.83M 1.42%
10,319
-867
-8% -$137K
META icon
14
Meta Platforms (Facebook)
META
$1.64T
$1.75M 1.36%
5,214
+443
+9% +$147K
AMZN icon
15
Amazon
AMZN
$2.66T
$1.46M 1.13%
8,780
-200
-2% -$34.2K
BRK.B icon
16
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.41M 1.09%
4,698
+683
+17% +$196K
NVDA icon
17
NVIDIA
NVDA
$4.91T
$1.22M 0.94%
41,420
+5,430
+15% +$149K
EAR
18
DELISTED
Eargo, Inc. Common Stock
EAR
$1.17M 0.91%
11,500
+1,750
+18% +$228K
EHTH icon
19
eHealth
EHTH
$47.3M
$1.15M 0.89%
45,000
-50,000
-53% -$1.66M
V icon
20
Visa
V
$682B
$1.11M 0.86%
5,134
+336
+7% +$72.1K
MA icon
21
Mastercard
MA
$480B
$1.03M 0.8%
2,875
+65
+2% +$22.5K
ACN icon
22
Accenture
ACN
$87.9B
$919K 0.71%
2,217
-150
-6% -$54.7K
TSLA icon
23
Tesla
TSLA
$1.43T
$885K 0.68%
2,511
-321
-11% -$108K
ADBE icon
24
Adobe
ADBE
$94.3B
$830K 0.64%
1,464
+43
+3% +$26.9K
NFLX icon
25
Netflix
NFLX
$290B
$825K 0.64%
13,700
-960
-7% -$61.3K
1
2 3 4

Similar funds

RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AG
Arctis Global San Juan, Puerto Rico $14.5M AUM 58.16% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
KM
Kabouter Management Chicago, Illinois $15.6M AUM 16.79% 1-Year Est. Return

DSC Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, DSC Advisors held 83 positions worth $129M, up 31% from $98.5M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

DSC Advisors deployed $24.2M of net new capital in Q4 2021, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 70,000 shares worth $6.18M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was eHealth, an estimated $1.66M trimmed.

  • DSC Advisors's largest Q4 2021 buy was BioMarin Pharmaceuticals: 70,000 shares worth $6.18M.
  • DSC Advisors added most to VYNE Therapeutics in Q4 2021, an estimated $1.73M increase.
  • DSC Advisors's biggest Q4 2021 reduction was eHealth, cutting an estimated $1.66M.
  • DSC Advisors fully exited Bristol-Myers Squibb in Q4 2021, selling an estimated $5.43M.
  • DSC Advisors's ten largest holdings make up 72% of its $129M portfolio in Q4 2021.
  • DSC Advisors opened 11 new positions and closed 13 in Q4 2021.
  • DSC Advisors's portfolio value rose 31% quarter-over-quarter to $129M.

Based on DSC Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.